ArticleCurrent oncology (Toronto, Ont.)2013
Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases.
Article in Current oncology (Toronto, Ont.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Bayesian meta-analysis on MRI-based radiomics for predicting EGFR mutation in brain metastasis of lung cancer.BMC medical imaging · 2025Pooled it
- Pooled it
- Trial
- A phase II study of anlotinib plus whole brain radiation therapy for patients with NSCLC with multiple brain metastases.Annals of medicine · 2024Trial
- Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.Advances in therapy · 2023Trial
- Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Predictive modeling of peripheral blood EGFR positivity in patients with advanced primary non-small cell lung cancer.Translational lung cancer research · 2026Article
- DriverNet: A Clinical and MRI-Based Framework for Noninvasive Pre-Treatment Molecular Triage in NSCLC Brain Metastases.Diagnostics (Basel, Switzerland) · 2026Article
- Initial biomarker testing strategies and clinical outcomes in advanced non-small cell lung cancer.iScience · 2026Article
- Real-World Survival Outcomes in EGFR-Mutant Advanced NSCLC Treated With EGFR TKIs: Insights From a Single-Center Clinical Data Warehouse Analysis in South Korea.Asia-Pacific journal of clinical oncology · 2026Article
- Phagocytic remodeling in CD74Translational cancer research · 2026Article
- A review of deep learning-based multimodal data integration of lung cancer.Clinical and experimental medicine · 2026Review
- Early predicting brain metastases of EGFR positive lung adenocarcinoma patients by CT radiomics.Physical and engineering sciences in medicine · 2026Article
- First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options-A Podcast.Targeted oncology · 2026Article
- Postoperative absence of residual intracranial tumor volume is associated with improved survival and intracranial disease control in non-small cell lung cancer brain metastases.Journal of neuro-oncology · 2025Article
- Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer.Clinical lung cancer · 2025Article
- Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis.Current oncology (Toronto, Ont.) · 2025Article
- The pharmacokinetics of capmatinib and its efficacy in non-small cell lung cancer treatment: a narrative review.Translational lung cancer research · 2025Review
- Prediction of biomarkers for brain metastasis in nonsmall cell lung cancer based on transcriptome sequencing.Medicine · 2025Article
- Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A.Acta neuropathologica communications · 2025Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of patients with brain metastases from non-small-cell lung cancer (nsclc) is poor. However, some reports suggest that patients with brain metastases at the time of initial diagnosis have a more favourable survival than do patients with advanced nsclc without brain metastases.
methodsIn a retrospective cohort of all new lung cancer patients seen at a Canadian tertiary centre between July 2005 and June 2007, we examined survival after a diagnosis of brain metastases for patients with brain metastases at initial diagnosis and patients who developed brain metastases later in their illness.
resultsDuring the 2-year period, 91 of 878 patients (10.4%) developed brain metastases. Median age in this cohort was 64 years. In 45, brain metastases were present at initial diagnosis, and in 46, brain metastases developed later in the course of the illness. Median survival in the entire cohort was 7.8 months. Survival after the diagnosis of brain metastases was similar for patients with brain metastases at diagnosis and later in the illness (4.8 months vs. 3.7 months, p = 0.53). As a result, patients who developed brain metastases later in their illness had a longer overall survival than did patients with brain metastases at diagnosis (9.8 months vs. 4.8 months). Among patients who received chemotherapy, the survival of patients with brain metastases at diagnosis was still poor (6.2 months).
conclusionsOur data show limited survival in patients with brain metastases from nsclc. Careful patient selection for more aggressive treatment approaches is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.